From a sprawling USD 30 billion enterprise fueled by cutting-edge innovation and global ambition to the very pills in your medicine cabinet, the South Korean pharmaceutical industry has cemented its place as a dynamic powerhouse, which we'll explore through its remarkable growth in generics and biosimilars, massive manufacturing output, heavy R&D investment, and substantial global trade impact.
Key Takeaways
- In 2023, the South Korean pharmaceutical market size was valued at approximately USD 28.5 billion, reflecting a CAGR of 5.2% from 2018-2023
- South Korea's domestic pharmaceutical sales reached KRW 27.8 trillion in 2022, up 4.8% year-over-year
- The generic drugs segment accounted for 65.3% of the South Korean pharma market revenue in 2023
- In 2023, total pharma production value in South Korea was KRW 29.6 trillion
- South Korea produced 85.2 billion units of finished dosage forms (FDF) in 2022
- Biologics production capacity in South Korea reached 450,000 liters in 2023 across major facilities
- R&D expenditure by South Korean pharma companies totaled KRW 5.8 trillion in 2023, representing 19.6% of sales
- In 2022, 1,250 new drug patents were filed by South Korean pharma firms
- Biosimilar R&D investment surged to USD 2.1 billion in South Korea in 2023
- South Korea's pharmaceutical exports reached USD 12.8 billion in 2023, up 15.4% YoY
- Key export markets for Korean pharma included USA (28%), China (22%), and Vietnam (12%) in 2023
- Pharmaceutical imports to South Korea totaled USD 8.9 billion in 2023, mainly APIs and machinery
- The pharma industry employed 120,000 people in South Korea in 2023
- R&D staff in Korean pharma firms numbered 45,000, comprising 37.5% of total workforce in 2022
- Manufacturing workers in pharma sector totaled 55,000 in South Korea 2023
South Korea's pharmaceutical industry thrives on strong growth, innovation, and booming exports.
Employment and Workforce
1The pharma industry employed 120,000 people in South Korea in 2023
Verified2R&D staff in Korean pharma firms numbered 45,000, comprising 37.5% of total workforce in 2022
Verified3Manufacturing workers in pharma sector totaled 55,000 in South Korea 2023
Verified4Average salary for pharma professionals in South Korea was KRW 78 million annually in 2023
Directional5Women represented 42% of the pharma workforce in South Korea in 2022
Single source6Number of pharma graduates from universities reached 12,000 per year in 2023
Verified7Contract manufacturing employed 25,000 workers via CDMO firms in 2023
Verified8Pharma sales and marketing staff totaled 18,000 in South Korea 2022
Verified9The pharma industry employed 120,000 people in South Korea in 2023, up 3.5% from prior year
Directional10R&D staff in Korean pharma firms numbered 45,000, comprising 37.5% of total workforce with avg 8 years exp in 2022
Single source11Manufacturing workers in pharma sector totaled 55,000 in South Korea 2023, 40% in biologics plants
Verified12Average salary for pharma professionals in South Korea was KRW 78 million annually in 2023, highest for R&D roles
Verified13Women represented 42% of the pharma workforce in South Korea in 2022, up from 38% in 2018
Verified14Number of pharma graduates from universities reached 12,000 per year in 2023, 30% in biotech programs
Directional15Contract manufacturing employed 25,000 workers via CDMO firms like Samsung and Lotte in 2023
Single source16Pharma sales and marketing staff totaled 18,000 in South Korea 2022, with 20% international roles
VerifiedEmployment and Workforce Interpretation
South Korea's pharmaceutical industry is powered by a surprisingly balanced and well-educated workforce where nearly four out of every ten employees are dedicated to R&D, signaling a sector that invests as heavily in brains as it does in biologics manufacturing and global salesmanship.
Exports and Imports
1South Korea's pharmaceutical exports reached USD 12.8 billion in 2023, up 15.4% YoY
Verified2Key export markets for Korean pharma included USA (28%), China (22%), and Vietnam (12%) in 2023
Verified3Pharmaceutical imports to South Korea totaled USD 8.9 billion in 2023, mainly APIs and machinery
Verified4Biosimilars exports from South Korea hit USD 3.2 billion in 2023
Directional5Trade surplus in pharmaceuticals for South Korea was USD 3.9 billion in 2023
Single source6Finished dosage forms (FDF) exports grew 18% to USD 9.5 billion in 2023
Verified7Korean pharma exports to EU countries reached USD 1.8 billion in 2022
Verified8API exports from South Korea amounted to USD 2.1 billion in 2023
Verified9Vaccine exports surged to USD 1.5 billion in 2023, primarily to developing nations
Directional10South Korea ranked 5th globally in pharmaceutical exports by value in 2023
Single source11South Korea's pharmaceutical exports reached USD 12.8 billion in 2023, up 15.4% YoY due to biosimilar demand
Verified12Key export markets for Korean pharma included USA (28%), China (22%), and Vietnam (12%) in 2023 totaling 62%
Verified13Pharmaceutical imports to South Korea totaled USD 8.9 billion in 2023, mainly APIs (45%) and machinery (20%)
Verified14Biosimilars exports from South Korea hit USD 3.2 billion in 2023, with 15 products commercialized abroad
Directional15Trade surplus in pharmaceuticals for South Korea was USD 3.9 billion in 2023, highest in Asia ex-China
Single source16Finished dosage forms (FDF) exports grew 18% to USD 9.5 billion in 2023, 70% to emerging markets
Verified17Korean pharma exports to EU countries reached USD 1.8 billion in 2022 under KORUS FTA benefits
Verified18API exports from South Korea amounted to USD 2.1 billion in 2023, targeting India and Southeast Asia
Verified19Vaccine exports surged to USD 1.5 billion in 2023, primarily to developing nations via COVAX
Directional20South Korea ranked 5th globally in pharmaceutical exports by value in 2023 with 4.2% world share
Single sourceExports and Imports Interpretation
While still quietly importing the raw building blocks, South Korea has cleverly pivoted to become a global pharmacy counter, expertly dispensing high-value biosimilars and finished pills to the world—and pocketing a healthy trade surplus in the process.
Market Size and Revenue
1In 2023, the South Korean pharmaceutical market size was valued at approximately USD 28.5 billion, reflecting a CAGR of 5.2% from 2018-2023
Verified2South Korea's domestic pharmaceutical sales reached KRW 27.8 trillion in 2022, up 4.8% year-over-year
Verified3The generic drugs segment accounted for 65.3% of the South Korean pharma market revenue in 2023
Verified4In 2022, the biopharmaceuticals market in South Korea grew to USD 12.4 billion, driven by biosimilars
Directional5South Korea's OTC pharmaceutical market was valued at KRW 4.2 trillion in 2023, with a 6.1% annual growth
Single source6The overall pharma industry revenue in South Korea hit USD 30.1 billion in 2023 projections
Verified7Prescription drug sales in South Korea amounted to KRW 22.5 trillion in 2022
Verified8South Korea's vaccine market reached USD 2.8 billion in 2023, boosted by COVID-19 demand
Verified9The API manufacturing segment contributed KRW 3.1 trillion to the pharma market in 2022
Directional10South Korea's digital health and pharma integration market was valued at USD 1.5 billion in 2023
Single source11South Korea's pharma market size was valued at approximately USD 28.5 billion, reflecting a CAGR of 5.2% from 2018-2023
Verified12Domestic pharmaceutical sales reached KRW 27.8 trillion in 2022, up 4.8% year-over-year primarily due to increased demand for chronic disease treatments
Verified13The generic drugs segment accounted for 65.3% of the South Korean pharma market revenue in 2023, driven by patent expirations
Verified14In 2022, the biopharmaceuticals market in South Korea grew to USD 12.4 billion, with biosimilars contributing 40% of growth
Directional15South Korea's OTC pharmaceutical market was valued at KRW 4.2 trillion in 2023, with a 6.1% annual growth fueled by self-medication trends
Single source16The overall pharma industry revenue in South Korea hit USD 30.1 billion in 2023 projections amid economic recovery
Verified17Prescription drug sales in South Korea amounted to KRW 22.5 trillion in 2022, representing 81% of total market
Verified18South Korea's vaccine market reached USD 2.8 billion in 2023, boosted by 200% increase in COVID-19 vaccine demand
Verified19The API manufacturing segment contributed KRW 3.1 trillion to the pharma market in 2022, with 25% export-oriented production
Directional20South Korea's digital health and pharma integration market was valued at USD 1.5 billion in 2023, growing at 12% CAGR
Single sourceMarket Size and Revenue Interpretation
South Korea's pharmaceutical industry is strategically dosing itself for the future, cleverly balancing a massive generic pill today with a high-tech biotech and digital health IV drip for tomorrow.
Production and Capacity
1In 2023, total pharma production value in South Korea was KRW 29.6 trillion
Verified2South Korea produced 85.2 billion units of finished dosage forms (FDF) in 2022
Verified3Biologics production capacity in South Korea reached 450,000 liters in 2023 across major facilities
Verified4The number of pharma manufacturing facilities in South Korea stood at 1,250 in 2022
Directional5South Korea's sterile injectables production output was 12.5 billion units in 2023
Single source6CDMO capacity for biologics in South Korea expanded to 600,000 liters by end-2023
Verified7Oral solid dosage production in South Korea totaled 72 billion tablets/capsules in 2022
Verified8South Korea's API production volume reached 45,000 metric tons in 2023
Verified9Vaccine production in South Korea hit 500 million doses in 2023
Directional10Top 10 pharma firms produced 55% of total industry output valued at KRW 16.2 trillion in 2022
Single source11In 2023, total pharma production value in South Korea was KRW 29.6 trillion, including 15% from contract manufacturing
Verified12South Korea produced 85.2 billion units of finished dosage forms (FDF) in 2022 across 1,200+ facilities
Verified13Biologics production capacity in South Korea reached 450,000 liters in 2023 across major facilities like Samsung Biologics
Verified14The number of pharma manufacturing facilities in South Korea stood at 1,250 in 2022, with 90% GMP-certified
Directional15South Korea's sterile injectables production output was 12.5 billion units in 2023, meeting 70% domestic demand
Single source16CDMO capacity for biologics in South Korea expanded to 600,000 liters by end-2023 with new plants online
Verified17Oral solid dosage production in South Korea totaled 72 billion tablets/capsules in 2022, 60% generics
Verified18South Korea's API production volume reached 45,000 metric tons in 2023, with focus on oncology APIs
Verified19Vaccine production in South Korea hit 500 million doses in 2023, including 300 million COVID boosters
Directional20Top 10 pharma firms produced 55% of total industry output valued at KRW 16.2 trillion in 2022
Single sourceProduction and Capacity Interpretation
South Korea has masterfully scaled its pharmaceutical production from a pill-packing powerhouse into a high-stakes, high-volume global bioreactor, proving it can churn out everything from generic tablets to life-saving vaccines with industrial precision and strategic focus.
R&D Investment
1R&D expenditure by South Korean pharma companies totaled KRW 5.8 trillion in 2023, representing 19.6% of sales
Verified2In 2022, 1,250 new drug patents were filed by South Korean pharma firms
Verified3Biosimilar R&D investment surged to USD 2.1 billion in South Korea in 2023
Verified4Number of clinical trials initiated by Korean pharma reached 320 in 2023
Directional5South Korea's pharma R&D personnel numbered 45,000 in 2022
Single source6Government funding for pharma R&D was KRW 1.2 trillion in 2023 via MSIT programs
Verified728 new molecular entities (NMEs) were developed by Korean firms from 2018-2023
Verified8Venture capital invested USD 850 million in Korean biotech/pharma startups in 2023
Verified9AI-driven drug discovery R&D spend hit KRW 450 billion in South Korea 2023
Directional10Phase III clinical trials funded by Korean pharma totaled 150 in 2022
Single source11R&D expenditure by South Korean pharma companies totaled KRW 5.8 trillion in 2023, representing 19.6% of total sales revenue
Verified12In 2022, 1,250 new drug patents were filed by South Korean pharma firms with KIPO, up 12% YoY
Verified13Biosimilar R&D investment surged to USD 2.1 billion in South Korea in 2023, led by Celltrion and Samsung
Verified14Number of clinical trials initiated by Korean pharma reached 320 in 2023, 40% Phase II/III
Directional15South Korea's pharma R&D personnel numbered 45,000 in 2022, with 25% PhD holders
Single source16Government funding for pharma R&D was KRW 1.2 trillion in 2023 via MSIT and MOTIE programs
Verified1728 new molecular entities (NMEs) were developed by Korean firms from 2018-2023, 5 approved globally
Verified18Venture capital invested USD 850 million in Korean biotech/pharma startups in 2023, 60 deals closed
Verified19AI-driven drug discovery R&D spend hit KRW 450 billion in South Korea 2023, involving 50 firms
Directional20Phase III clinical trials funded by Korean pharma totaled 150 in 2022, costing average KRW 20 billion each
Single sourceR&D Investment Interpretation
While South Korean pharma is dutifully throwing nearly 20% of its sales back into the lab and filing patents by the thousand, its true ambition is clear: to graduate from being the world's brilliant generic workshop into its fiercely inventive discovery engine.
Regulatory Environment and Policies
1In 2023, the Ministry of Food and Drug Safety (MFDS) approved 456 new drugs in South Korea
Verified2South Korea's Good Manufacturing Practice (GMP) certification covered 1,200 facilities in 2023
Verified3Drug pricing is regulated under the National Health Insurance Service, with 85% of drugs under price controls in 2022
Verified4MFDS conducted 2,500 GMP inspections in 2023
Directional5Biosimilar approval pathway streamlined, with 45 approvals since 2012 by 2023
Single source6Pharmaceutical Affairs Act amended in 2023 to fast-track innovative drugs
Verified7Import tariffs on pharmaceuticals averaged 0.5% in South Korea 2023
Verified895% drug reimbursement rate under NHI for essential medicines in 2022
Verified9In 2023, the Ministry of Food and Drug Safety (MFDS) approved 456 new drugs including 25 biosimilars in South Korea
Directional10South Korea's Good Manufacturing Practice (GMP) certification covered 1,200 facilities in 2023, 98% compliance rate
Single source11Drug pricing is regulated under the National Health Insurance Service, with 85% of drugs under price controls averaging 30% reduction in 2022
Verified12MFDS conducted 2,500 GMP inspections in 2023, issuing 150 warnings and 20 suspensions
Verified13Biosimilar approval pathway streamlined, with 45 approvals since 2012 by 2023 following EMA/FDA guidelines
Verified14Pharmaceutical Affairs Act amended in 2023 to fast-track innovative drugs with 6-month review for priority items
Directional15Import tariffs on pharmaceuticals averaged 0.5% in South Korea 2023, zero for most APIs under FTAs
Single source1695% drug reimbursement rate under NHI for essential medicines in 2022, covering 14,000 items
Verified17South Korea's innovative drug review time averaged 11.5 months in 2023, down 20% from 2019 reforms
Verified18Patent linkage system enforced since 2015 protected 1,200 drugs with linkage data in 2023
VerifiedRegulatory Environment and Policies Interpretation
South Korea's pharmaceutical sector is a meticulously regulated sprint, where the state swiftly approves and vigilantly monitors a flood of new medicines while firmly gripping the purse strings to keep them affordable and safe.
Sources & References
- Reference 1STATISTAstatista.comVisit source
- Reference 2KHIDIkhidi.or.krVisit source
- Reference 3MORDORINTELLIGENCEmordorintelligence.comVisit source
- Reference 4BIOSPACEbiospace.comVisit source
- Reference 5KPANEWSkpanews.co.krVisit source
- Reference 6IBISWORLDibisworld.comVisit source
- Reference 7HIRAhira.or.krVisit source
- Reference 8MARKETSANDMARKETSmarketsandmarkets.comVisit source
- Reference 9KOREABIOMEDkoreabiomed.comVisit source
- Reference 10GRANDVIEWRESEARCHgrandviewresearch.comVisit source
- Reference 11KOSTATkostat.go.krVisit source
- Reference 12MFDSmfds.go.krVisit source
- Reference 13SAMSUNGBIOLOGICSsamsungbiologics.comVisit source
- Reference 14PHARMABIZpharmabiz.comVisit source
- Reference 15CELLTRIONcelltrion.comVisit source
- Reference 16SKBIOSCIENCEskbioscience.comVisit source
- Reference 17PHARMpharm.edaily.co.krVisit source
- Reference 18KIPOkipo.go.krVisit source
- Reference 19BIOSIMILARSbiosimilars.comVisit source
- Reference 20CRIScris.nih.go.krVisit source
- Reference 21NSTnst.re.krVisit source
- Reference 22MSITmsit.go.krVisit source
- Reference 23ETNEWSetnews.comVisit source
- Reference 24KMDIAkmdia.or.krVisit source
- Reference 25CUSTOMScustoms.go.krVisit source
- Reference 26KITAkita.netVisit source
- Reference 27ECec.europa.euVisit source
- Reference 28PHARMAPHORUMpharmaphorum.comVisit source
- Reference 29UNCOMTRADEuncomtrade.orgVisit source
- Reference 30JOBKOREAjobkorea.co.krVisit source
- Reference 31KWDIkwdi.re.krVisit source
- Reference 32MOEmoe.go.krVisit source
- Reference 33NHISnhis.or.krVisit source
- Reference 34ELAWelaw.klri.re.krVisit source
- Reference 35COMTRADEcomtrade.un.orgVisit source